Navigation Links
Researchers identify a 'life-and-death' molecule on chronic leukemia cells
Date:5/30/2012

  • SMIP-016 is a promising experimental drug that kills chronic leukemia cells.
  • The drug targets a protein called CD37, but it wasn't known how this kills leukemia cells.
  • This study showed unexpectedly that CD37 helps regulate both cell-death and cell-survival signals, explaining how the drug works and how it might be improved.

COLUMBUS, Ohio A new study has identified a life-and-death signaling role for a molecule on the surface of the immune cells involved in the most common form of chronic leukemia. The finding could lead to more effective therapy for chronic lymphocytic leukemia (CLL), an as yet incurable cancer that occurs in more than 16,000 Americans annually.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James), examines how an experimental drug called SMIP-016 kills CLL cells.

Earlier work by the same researchers showed that the drug targets a molecule called CD37, which is found on the surface of CLL cells. In this new study, the researchers discovered that the CD37 molecule has two regions that can concurrently activate two separate pathways in CLL cells, one that leads to cell death and another that promotes cell survival.

The findings show SMIP-016 activates the "death" part of the molecule, and they suggest that blocking the "survival" part of the molecule could improve the drug's effectiveness, the researchers say.

The study is published in the May issue of journal Cancer Cell.

"These findings open new possibilities for the use of immune-based therapy for treating CLL," says principal investigator Dr. John Byrd, a CLL specialist and professor of Medicine, of Medicinal Chemistry and of Veterinary Biosciences.

"We are already targeting the cell-death pathway using SMIP-016, and we might be able to optimize the drug's effectiveness by simultaneously blocking the cell-survival region of the molecule with a second antibody," he says.

Byrd notes that drugs that can block the cell-survival pathway already exist.

"We were very surprised and excited to find that CD37 is directly involved in regulating survival and cell-death pathways," says first author Rosa Lapalombella, a research scientist in Byrd's laboratory. "That's not usually the case for molecules of this kind."

Co-principal investigator Dr. Natarajan Muthusamy, associate professor of Medicine, notes that CD37 belongs to a family of molecules called tetraspanins, which usually only facilitate signaling by bringing together other molecules that when combined issue signals.

"This work is a great example of collaborative research involving several laboratories," says researcher and co-principal investigator Dr. Michael Freitas, associate professor of molecular virology, immunology and medical genetics, whose laboratory contributed to the global proteomic work of how CD37 signals. "The support for, and emphasis on, team science is a major driving strength of Ohio State and contributed to this project's findings," he says.

Byrd hopes to begin a clinical trial soon that tests SMIP-016 combined with a drug that blocks the survival pathway.

"Overall, these findings reinforce our belief SMIP-016 could be an effective agent for treating CLL and other malignancies that sometimes express the CD37 protein, including non-Hodgkin's lymphoma and acute lymphoblastic leukemia," says Byrd, who is the D. Warren Brown Chair of Leukemia Research.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
2. Researchers restore neuron function to brains damaged by Huntingtons disease
3. UC San Diego researchers receive new CIRM funding
4. Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture
5. McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones
6. Barrow researchers use magic for discoveries
7. Researchers present new findings for novel pancreatic cancer vaccine
8. Dartmouth researchers investigate the cognitive effects of athlete head impacts
9. Fish Pedicure a Recipe for Bacterial Infection, Researchers Warn
10. Fox Chase researchers find no disparities in imaging before breast cancer surgery
11. Researchers undertake radical new cancer survivorship study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House ... most popular and least understood books in the Holy Scriptures, Revelation. The Book of ... baffled scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/2/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... , and named its founder as Diplomat,s chief information ... Tennessee , will operate under Diplomat subsidiary Envoy ... for health care partners to include IT outsourcing, consulting, ... "In an interoperable world, technology delivers comprehensive insight and ...
Breaking Medicine Technology: